iRhythm Holdings is a leading digital healthcare company that creates trusted solutions that detect predict and prevent disease. The firm was incorporated in Delaware in 2006 as iRhythm Technologies and later succeeded by iRhythm Holdings in 2025. Its principal activity is the design development and commercialization of a wearable biosensor and cloud based analytics platform that together provide ambulatory cardiac monitoring. The biosensor is a wire free patch that adheres to the chest and records electrocardiogram data continuously for up to 14 days without requiring recharging. The accompanying software uses proprietary algorithms to analyze the recorded data and generate reports that highlight arrhythmia events. The system has received regulatory clearance from the FDA CE marking in Europe and approval from Japan’s PMDA where applicable. iRhythm operates its own Medicare enrolled independent diagnostic testing facilities where trained technicians receive the devices upload the data to a secure cloud and produce final reports for prescribing physicians. The company reports having delivered more than twelve million patient reports and accumulated almost three billion hours of heartbeat data since its inception.

iRhythm generates the majority of its revenue from providing ambulatory cardiac monitoring services rather than selling devices outright. When a physician orders long term continuous monitoring or mobile cardiac telemetry the company supplies the appropriate patch and through its network of independent diagnostic testing facilities collects the ECG data processes it with its ZEUS software and delivers a comprehensive report. Payment is obtained from third party payors including private insurers and government programs such as Medicare and Medicaid. In 2025 approximately 83 percent of total revenue came from third party payors with about 24 percent of the total derived directly from the Medicare program. The company also earns revenue from the distribution of its products in select international markets including the United Kingdom the European Union and Japan where it has established commercial partnerships and obtained local regulatory approvals. Additionally iRhythm receives income from licensing arrangements such as the technology license agreement with BioIntelliSense which provides access to complementary sensing technologies. The service model ensures recurring revenue as each monitoring episode represents a billable event and the company benefits from the aging population and rising prevalence of arrhythmias.

iRhythm is recognized as a market leader in the ambulatory cardiac monitoring sector particularly in the niche of long term continuous monitoring. Industry estimates indicate that the company accounts for more than 70 percent of long term continuous monitoring procedures performed in the United States. Its main competitors include patch based monitoring providers such as BioTelemetry now part of Royal Philips Preventive Solutions now part of Boston Scientific and Bardy Diagnostics now part of Baxter International. The firm also competes with manufacturers of traditional short term monitors such as GE Healthcare Philips Healthcare Spacelabs Healthcare Welch Allyn and Mortara Instrument. iRhythm’s competitive advantages stem from its 14 day wear time which allows capture of intermittent arrhythmias that shorter monitors often miss. The patch design is water resistant and lightweight leading to patient compliance rates above 98 percent. The company’s proprietary deep learning algorithms have been validated in multiple studies to match or exceed the accuracy of expert cardiologists in detecting a wide range of arrhythmia types. Clinical evidence from the CAMELOT and AVALON real world studies demonstrates that iRhythm’s service delivers higher diagnostic yield reduces the need for repeat testing and lowers emergency department visits hospitalizations and overall health care expenditures compared with standard Holter or event based monitoring. These outcomes support the company’s value proposition to payers who are increasingly focused on cost effective first test resolution and improved patient outcomes.

iRhythm serves a diverse customer base that includes physicians hospitals health systems and independent diagnostic testing facilities that prescribe ambulatory cardiac monitoring for patients suspected of having arrhythmias. The typical patient is someone experiencing infrequent or asymptomatic symptoms such as palpitations dizziness or unexplained stroke risk who needs extended monitoring to capture transient cardiac events. While the filing does not list specific customer names the company’s commercial efforts target cardiology electrophysiology primary care neurology and other specialty practices. iRhythm also works with large integrated delivery networks and risk bearing entities that seek to implement population health strategies and reduce avoidable hospitalizations. On the payer side revenue is derived from Medicare commercial insurers and Medicaid programs that reimburse for the monitoring service when it is deemed medically necessary. The company’s ability to provide seamless electronic health record integration and patient friendly reporting tools further strengthens its relationships with both providers and payors.